Skip to content
value.today

DOR Biopharma Inc.

Formerly ENDOREX CORP, IMMUNOTHERAPEUTICS INC

Total raised
$14 M
4 rounds on record
Latest round
$6 M
Jun 2010
First round on record
Dec 2008
Today
Went public
See the company page

DOR Biopharma Inc. is listed today as Soligenix, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of DOR Biopharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2017$2 MPrivate placement after listingUnder $2 million

DOR Biopharma Inc.: Private sale, Nov 2017

Investors in this round

6 investors had bought by the notice of Nov 8, 2017: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$137,480
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adam T. Rumage · Executive Officer
  • Christopher J. Schaber, PhD · Executive Officer, Director
  • Karen Christopher Krumeich · Executive Officer
  • Oreola Christopher Donini, PhD · Executive Officer
  • R. Christopher Cavalli, PhD · Executive Officer
  • Richard C. Straube, MD MSc · Executive Officer
  • Gregg A. LaPointe, CPA · Director
  • Jerome B. Zeldis, PhD · Director
  • Keith L. Brownlie, CPA · Director
  • Marco M. Brughera, DVM · Director
  • Robert J. Rubin, MD · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Aegis Capital Corp. (CRD 15007) · New York, New YorkSold in CA, NY, PA

Remarks in the notice

  • On fees: “Additionally, the Issuer agreed to (i) sell, for the price of $100, the placement agent a warrant to purchase 19,640 shares of common stock at a price of $2.50 per share and (iii) reimburse certain expenses of the placement agent.”

Signed by Christopher J. Schaber, Ph.D, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 8, 2017. Read the notice at the SEC.

equitySEC
Apr 2013$2 MPrivate placement after listingUnder $2 million

DOR Biopharma Inc.: Private sale, Apr 2013

Investors in this round

1 investor had bought by the notice of May 3, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher J. Schaber, Ph.D. · Executive Officer, Director
  • Joseph M. Warusz, C.P.A. · Executive Officer
  • Kevin J. Horgan, M.D. · Executive Officer
  • Robert N. Brey, Ph.D. · Executive Officer
  • Gregg A. Lapointe, C.P.A. · Director
  • Jerome B. Zeldis, M.D., Ph.D. · Director
  • Keith L. Brownlie, C.P.A. · Director
  • Robert J. Rubin, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Company issued 1,034,483 shares of common stock to Intrexon Corp pursuant to an Exclusive Channel Collaboration Agreement. No cash was received. The amount entered is based solely on the closing price of the Company's common stock of $1.45 on 4/26/13.”

Signed by Christopher J. Schaber, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 3, 2013. Read the notice at the SEC.

equitySEC
Jun 2010$6 MNo. 4$2 to $10 million

DOR Biopharma Inc.: Raise no. 4, Jun 2010

Investors in this round

46 investors had bought by the notice of Jul 2, 2010: 46 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$122,233
Finders' fees
$40,744
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian L. Hamilton, M.D., Ph.D. · Executive Officer
  • Christopher J. Schaber, Ph.D. · Executive Officer, Director
  • Christopher P. Schnittker, C.P.A. · Executive Officer
  • Evan J. Myrianthopoulos · Executive Officer, Director
  • Robert N. Brey, Ph.D. · Executive Officer
  • Cyrille F. Buhrman · Director
  • Gregg A. Lapointe, C.P.A., M.B.A. · Director
  • Robert J. Rubin, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Griffin Securities, Inc. (CRD 43229) · broker-dealer Adrian Stecyk (CRD 43229) · New York, New YorkSold in CA, CT, FL, IL, MD, MN, NJ, NY, TX, WI
  • National Securities Corporation (CRD 7569) · broker-dealer Brian A. Friedman (CRD 7569) · Seattle, WashingtonSold in CA, CT, FL, IL, MD, MN, NJ, NY, TX, WI

Remarks in the notice

  • On fees: “In addition to cash fees, the brokers received Warrant Shares totalling 706,011 and the Finder received Warrant Shares totalling 235,337.”

Signed by Christopher P. Schnittker, Vice President, Controller. Source: SEC Form D, newest notice filed Jul 2, 2010. Read the notice at the SEC.

equity, optionsSEC
Feb 2009$5 MNo. 3$2 to $10 million

DOR Biopharma Inc.: Raise no. 3, Feb 2009

Investors in this round

1 investor had bought by the notice of Feb 27, 2009: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
$4,500,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • Christopher J Schaber · Executive Officer, Director
  • Evan Myrainthopoulos · Executive Officer, Director
  • James Clavijo · Executive Officer
  • Cyrille F Buhrman · Director
  • James S Kuo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Clavijo, Secretary/Treasurer. Source: SEC Form D, newest notice filed Feb 27, 2009. Read the notice at the SEC.

equitySEC
Jan 2009$2 MNo. 2$2 to $10 million

DOR Biopharma Inc.: Raise no. 2, Jan 2009

Investors in this round

6 investors had bought by the notice of Feb 3, 2009: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$1
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
$114,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • Christopher J Schaber · Executive Officer, Director
  • Evan Myrianthopoulos · Executive Officer, Director
  • James Clavijo · Executive Officer
  • Robert N Brey · Executive Officer
  • Cyrille Buhrman · Director
  • James S Kuo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Clavijo, Controller/Treasurer. Source: SEC Form D, newest notice filed Feb 3, 2009. Read the notice at the SEC.

equity, optionsSEC
Dec 2008$2 MNo. 1Under $2 million

DOR Biopharma Inc.: Raise no. 1, Dec 2008

Investors in this round

1 investor had bought by the notice of Dec 5, 2008: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$1,500,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • Christopher J Schaber · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Clavijo, Treaurer/secretary. Source: SEC Form D, newest notice filed Dec 5, 2008. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Soligenix, Inc., its revenue in fiscal 2024 came from these product and service lines: Grant revenue $120,000 (100%).

    Annual report (SEC XBRL) · Dec 2024

  • DOR Biopharma Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2017).

    SEC Form D · Nov 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2017

Products and services#

No products or services of DOR Biopharma Inc. are on record.

Investors#

No investor of DOR Biopharma Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 46 investors.

Largest shareholders today

Institutions holding Soligenix, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by DOR Biopharma Inc.
NameRoleNamed in
Adam T. RumageExecutive officerNov 2017
Christopher J. Schaber, PhDExecutive officerNov 2017
Karen Christopher KrumeichExecutive officerNov 2017
Oreola Christopher Donini, PhDExecutive officerNov 2017
R. Christopher Cavalli, PhDExecutive officerNov 2017
Richard C. Straube, MD MScExecutive officerNov 2017
Christopher J. Schaber, Ph.D.Executive officerMay 2013
Joseph M. Warusz, C.P.A.Executive officerMay 2013
Kevin J. Horgan, M.D.Executive officerMay 2013
Robert N. Brey, Ph.D.Executive officerMay 2013
Brian L. Hamilton, M.D., Ph.D.Executive officerJul 2010
Christopher P. Schnittker, C.P.A.Executive officerJul 2010
Evan J. MyrianthopoulosExecutive officerJul 2010
Christopher J SchaberExecutive officerFeb 2009
Evan MyrainthopoulosExecutive officerFeb 2009
James ClavijoExecutive officerFeb 2009
Evan MyrianthopoulosExecutive officerFeb 2009
Robert N BreyExecutive officerFeb 2009
Christopher J. Schaber, PhDDirectorNov 2017
Gregg A. LaPointe, CPADirectorNov 2017
Jerome B. Zeldis, PhDDirectorNov 2017
Keith L. Brownlie, CPADirectorNov 2017
Marco M. Brughera, DVMDirectorNov 2017
Robert J. Rubin, MDDirectorNov 2017
Christopher J. Schaber, Ph.D.DirectorMay 2013
Gregg A. Lapointe, C.P.A.DirectorMay 2013
Jerome B. Zeldis, M.D., Ph.D.DirectorMay 2013
Keith L. Brownlie, C.P.A.DirectorMay 2013
Robert J. Rubin, M.D.DirectorMay 2013
Cyrille F. BuhrmanDirectorJul 2010
Evan J. MyrianthopoulosDirectorJul 2010
Gregg A. Lapointe, C.P.A., M.B.A.DirectorJul 2010
Christopher J SchaberDirectorFeb 2009
Cyrille F BuhrmanDirectorFeb 2009
Evan MyrainthopoulosDirectorFeb 2009
James S KuoDirectorFeb 2009
Cyrille BuhrmanDirectorFeb 2009
Evan MyrianthopoulosDirectorFeb 2009

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.